IMS Health Real-World Evidence Solutions at ISPOR November 2015
•
3 likes•2,095 views
Welcome to the IMS Health Real-World Evidence (RWE) Solutions program of activities at the forthcoming ISPOR 18th Annual European Congress in Milan. We invite you to join us at more than 70 presentations that spotlight exciting innovations and applications of outcomes research and RWE. And please visit us at our booth to learn more about our pioneering efforts including the e360TM technology suite, RWD Catalogue with 1,800+ data sources identified, and the newly launched RWE Dictionary. Full details of our ISPOR schedule can be found in the brochure.
Report
Share
More Related Content
What's hot
What's hot (20)
Similar to IMS Health Real-World Evidence Solutions at ISPOR November 2015
Similar to IMS Health Real-World Evidence Solutions at ISPOR November 2015 (20)
More from IMSHealthRWES
More from IMSHealthRWES (14)
Recently uploaded
Recently uploaded (20)
IMS Health Real-World Evidence Solutions at ISPOR November 2015
- 1. ISPOR 18th Annual European Congress 7-11 November 2015, Milan, Italy Join the IMS Health Symposium “Enriched real-world data (RWD) studies: Tapping into the growing use of patient-level data to optimize observational study design and execution” Meet the largest expert community in RWE – now including our new colleagues from Cegedim Strategic Data Discover the findings from our latest research IMS Health Real-World Evidence Solutions at ISPOR, November 2015
- 2. 2 IMS Health Our Distinctive Approach IMS Health has taken a holistic approach to real-world evidence (RWE) in pursuit of the most robust and insightful views of patient outcomes. With the breadth and depth of our capabilities, we are uniquely positioned to generate and use RWE globally. Applying the appropriate scientific and commercial lens and latest techniques to anonymous real-world data (RWD) is critical to realizing the value of RWE in healthcare decisions. IMS Health Real-World Evidence Solutions IMS Health can uniquely support all elements of the RWE ecosystem – an environment where all the components of RWE come together for a consistent, insightful view of what really happens in healthcare. An environment which, for the first time, helps all functions realize its potential. Technology- Enabled Analytics Real-World Data Services and Engagement IMS HEALTH REAL-WORLD EVIDENCE SOLUTIONS Accesstherightreal-world da ta Analyzethedata Create datasets Apply the insights Introducing the RWE ecosystem Real-World Data Identify and access the most appropriate data sources while ensuring patient privacy •The broadest and deepest collection of scientifically-validated, anonymous patient-level data assets •Complement fit-for-purpose data by custom data sourcing to close data gaps Technology-Enabled Analytics Create consistent data models empowering analyses and leveraging innovative technologies •Extraction, analysis and visualization of RWD with IMS Health’s E360TM technology suite •Sophisticated data linkage and interpretation Services and Engagement Analyze RWD using scientific rigor, clear governance and advanced analytic and processing capabilities •Market Access & HTA •Health Economics •Outcomes Research •Pharmacoepidemiology & Drug Safety •Commercial Analytics
- 3. ISPOR 18th Annual European Congress, November 2015, Milan, Italy 3 Welcome to IMS Health at ISPOR Milan, 2015 Increased emphasis on RWE and a concentrated focus on patient benefits have placed outcomes research (OR) at the heart of healthcare decision making. Reflecting its growing importance and potential is the need for more compelling, impactful OR across the spectrum of evidence evaluation. Approaches that can extend existing RWD and accelerate its power to answer critical questions are key to achieving this goal. IMS Health is committed to innovation in data collection to overcome the limitations of traditional methods and drive richer insights and faster results. We look forward to sharing the research this has enabled during the ISPOR 18th Annual European Congress as progress towards “closing the gap” in OR continues. Please join us during the event. An overview of our activities can be found in this brochure. We hope to see you in Milan! #1 Partner of Choice for RWE •Largest, international fit-for-purpose RWD portfolio available with 500+ million anonymous longitudinal patient data records in 25+ markets •Partnerships and data sourcing capabilities to bring clients data that is right for their needs •3,500+ publications building healthcare knowledge •Leading edge technology and analytics to enhance understanding of patient outcomes, healthcare costs, pharmacoepidemiology, drug safety and product value •Experts in 20+ markets with deep specialism in RWE, HTA and payer requirements to translate insights into actions IMS Health is excited to announce that Cegedim Strategic Data has joined our Real-World Evidence Solutions team, boosting our RWD assets and analytical expertise and confirming our role as the partner of choice for RWE.
- 4. IMS Health Symposium Wednesday, 11 November 4IMS Health Real-World Evidence Solutions “Enriched real-world data (RWD) studies: Tapping into the growing use of patient-level data to optimize observational study design and execution” Pharmaceutical manufacturers face a challenge in meeting increased demand for RWE through prospective observational studies in a cost-effective and timely way. Although many are comfortable looking purely to electronic patient data (eg, EMRs) for retrospective database analysis, they are not always aware of how these sources can support primary data collection to generate the rich clinical data needed. Enriched RWD studies – observational studies supplemented by de novo data collection – are one such alternative. These may include the use of technology embedded into an EMR system to prompt for additional variables to be collected during patient visits and/or site or patient randomization. Pragmatic trials with EMR follow-up can also be used to evaluate the impact of approaches to enhancing adherence, with modest expenditures compared to RCTs. In addition, data can be collected directly from the patient, providing missing insights about their experience when relying on physician-reported data alone. This symposium will discuss these processes as well as applications for enriched RWD studies, including both for targeted use and for the creation of more enduring evidence platforms. We will show how they can lead to more robust and efficient research, leveraging case studies to demonstrate the benefit for stakeholders. Members of our global Real-World Evidence Solutions team will be on hand during ISPOR to discuss your needs in RWE and explain how we can help you address them. Come and see us at the IMS Health stand in the exhibition area (Nos 616, 617, 700, 701) to discover more about our expertise and capabilities, which have recently expanded with the exciting addition of Cegedim Strategic Data. Visit us at the IMS Health stand
- 5. IMS Health Symposium Agenda IMS Health Symposium Chair 5ISPOR 18th Annual European Congress, November 2015, Milan, Italy 07:30–07:40 Introduction: RWE creating new approaches for observational research Alison Bourke, MSc, MRPharm.S, FISPE, (Chair) Scientific Director, Real-World Evidence Solutions, IMS Health, UK 07:40–08:00 Next generation observational research: Enriched RWD studies Joshua Hiller, MBA, Senior Principal, Real-World Evidence Solutions, IMS Health, UK Pierre Engel, Pharm.D, MPH, PhD, Associate Director Epidemiology, Real-World & Late Phase Research, Quintiles, France 08:00–08:20 How to benefit from enriched RWD studies: Reflections from a study sponsor Andrew Shaw, BSc, PhD, RWE Alliance Director, AstraZeneca, UK Lance Brannman, PhD, Group Director, Health Economics & Payer Analytics, AstraZeneca, USA; Member of the Board, Centre for Health Economics, Gothenburg University, Sweden 08:20–08:30 Moderated Q&A Alison Bourke (Chair) Proceedings from the symposium can be obtained from IMS Health. To receive a copy, please email Angelika Boucsein at Aboucsein@de.imshealth.com Continental breakfast will be available for all symposium attendees Alison Bourke, MSc, MRPharm.S, FISPE Alison Bourke is a Scientific Director, RWE Solutions at IMS Health. She has over 25 years of experience working with primary care patient data resources in the UK and a particular interest in their use to explore innovative scientific methodologies. Previously, Alison headed the research team at CSD Medical Research UK, providing primary care data and support for a range of studies, including pharmacoepidemiology and health outcomes research. She pioneered innovative linking ‘pseudonymization at source’ technology and was instrumental in setting up the Health Improvement Network (THIN), bringing access to 12 million pseudonymized patient records. A trained pharmacist, Alison has also held roles at BMS where she analyzed one of the first computer- collected safety studies, and Cegedim INPS where she supported the successful launch of GPRD. Continued overleaf...
- 6. IMS Health Real-World Evidence Solutions 6 IMS Health Symposium Speakers Joshua Hiller, MBA Joshua Hiller is a Senior Principal, RWE Solutions at IMS Health, supporting the strategic planning and development of the company’s capabilities for data sourcing, integration, analytics and studies. He is also currently serving as Alliance Director in IMS Health’s collaboration with AstraZeneca for the advancement of RWE. During a career that includes roles in market analytics, government and healthcare consulting in both the USA and UK, Joshua has led a wide range of projects for clients in the pharmaceutical and biotech sector as well as industry associations. He has extensive experience in pharmaceutical pricing, contracting, market landscape development, supply management, cross border trade, lifecycle management, competitive defense, generics market drivers and account management, with expertise across US and European markets. Pierre Engel, Pharm.D, MPH, PhD Dr. Pierre Engel is Associate Director Epidemiology, Real-World & Late Phase Research at Quintiles, France, managing a team of epidemiologists involved mainly in Post Authorisation Safety Studies (PASS). He has eight years of experience in international observational research including roles as Epidemiologist at a medium-size CRO and at INSERM where he was in charge of developing epidemiological studies on existing data in women’s health. Pierre has strong expertise in the design, scientific oversight, analysis and reporting of observational studies as well as epidemiology methods, CER, pharmacoepidemiology, and database research. He is a member of both the Steering Group and HTA Working Group at ENCePP, is actively involved as an epidemiologist on many large international programs, and has designed numerous PASS endorsed by the EMA’s Pharmacovigilance Risk Assessment Committee. Andrew Shaw, BSc, PhD Dr. Andy Shaw is RWE Alliance Director at AstraZeneca, UK, where he focuses on continuing to develop the company’s RWE capabilities globally, particularly in the respiratory and oncology therapeutic areas. He has established and maintained strong partnerships with many external stakeholders, including IMS Health and Quintiles. Andy began his career as a lecturer at the University of London before moving into the pharmaceutical industry. He has more than 18 years of experience at AstraZeneca, both in the UK and for a time in Japan, in positions that have primarily focused on generating clinical data for regulatory submissions. More recently, during the last 4-5 years, Andy’s focus has shifted to generating evidence outside of clinical trial settings for a multitude of purposes. Lance Brannman, PhD Dr. Lance Brannman is Group Director, Health Economics & Payer Analytics for respiratory, inflammation and autoimmune diseases at AstraZeneca, USA. He was previously responsible for cardiovascular & metabolic diseases, CNS diseases and infection, with accountability in both roles for delivering global health economics projects. He is also a Member of the Board at the Centre for Health Economics, Gothenburg University, Sweden. Lance spent several years as an academic before joining the pharmaceutical industry where he has held various senior-level positions in health economics and outcomes research at AstraZeneca and Novo Nordisk A/S. He has extensive experience in pharmacoeconomics spanning modeling, technical writing, RWE, clinical trial design and PRO administration, as well as expertise in microeconomic analysis, statistics & econometrics, and programming.
- 7. ISPOR 18th Annual European Congress, November 2015, Milan, Italy 7 Live Sessions with IMS Health Book a demonstration of IMS Health’s E360™ technology suite IMS Health RWE experts will be running demonstrations of our powerful E360™ data platform technology and applications suite which allows researchers to answer all questions – from the routine to the most challenging – in a standardized, intuitive way. Schedule your individual presentation at the IMS Health stand or by emailing Peter Riebel at Priebel@de.imshealth.com Issue Panel • The cost of no Europe - Localized or centralized assessment of relative efficacy – 10 November, 13:45–14:45 Workshops • Evidence synthesis in HTA decision making – 10 November, 08:45–09:45 • Network meta analysis modeling for dose response and class effects – 11 November, 15:00–16:00 Research Podiums • Hospital cost and length of stay in chronic heart failure – 9 November, 16:15–16:30 • Cost-effectiveness in COPD – 9 November, 16:30–16:45 See pages 8–11 for further details.
- 8. 9NOV CV3 THE COST AND LENGTH OF STAY OF HOSPITAL EMERGENCY DEPARTMENT VISITS FOR CHRONIC HEART FAILURE PATIENTS IN CANADA Fischer AA, Liu N, Borelli R, Zaour N, Barbeau M Research Podium CE4 ASSESSING THE COST-EFFECTIVENESS OF USING ACLIDINIUM BROMIDE 400 µG /FORMOTEROL FUMARATE DIHYDRATE 12 µG COMPARED TO ACLIDINIUM BROMIDE 400 µG IN THE MANAGEMENT OF MODERATE TO SEVERE CHRONIC OBSTRUCTIVE PULMONARY DISEASE Ramos M, Haughney J, Henry N, Lindner L, Lamotte M Research Podium PCV53 CARDIOVASCULAR EVENT RATES IN A HIGH-RISK GENERAL POPULATION COHORT OF 340,000 INDIVIDUALS IN THE UNITED KINGDOM Ansell D, Khan I, Proudfoot C, Gbenedio T, Joulain F, Pockett RD, Catterick D, Gooch K Research Poster PCV63 AN ASSESMENT OF ENOXAPARINE BENEFIT ON HEALTHCARE BUDGET IN SPAIN Delgado M, Restovic G, Planellas L, Rubio M, Miñarro C Research Poster PCV67 MEDICAL COST OF PATIENTS WITH NON-VALVULAR ATRIAL FIBRILLATION (NVAF) AND TREATED WITH VITAMIN K ANTAGONISTS (VKAS) ACCORDING TO INR CONTROL STATUS IN SPAIN Postema R, Bardoulat I, Roset M, Maurel F, Lefevre C, Evans D Research Poster PCV85 AN EPIDEMIOLOGICAL EVALUATION OF THE INCIDENCE OF DEEP VENOUS THROMBOSIS AND PULMONARY EMBOLISM IN PATIENTS WITH HIP OR KNEE REPLACEMENT SURGERY AND OF ITS IMPACT ON THE AVERAGE LENGTH OF STAY AND HOSPITALIZATION COST Chevalier P, Lamotte M Research Poster PCV89 A COMPARISON OF TWO LOW-MOLECULAR-WEIGHT HEPARINS (LMWHS) IN TERMS OF COST PER PATIENT Planellas L, Miñarro C, Restovic G, Delgado M, Rubio M Research Poster PCV90 THE COST OF ACUTE CARE HOSPITALIZATIONS ASSOCIATED WITH CHRONIC HEART FAILURE IN CANADA Fischer AA, Liu N, Borelli R, Barbeau M, Zaour N Research Poster PCV91 AN EPIDEMIOLOGICAL EVALUATION OF THE IMPACT OF PERCUTANEOUS CORONARY INTERVENTIONS ON THE HOSPITALIZATION COST, LENGTH OF STAY AND MORTALITY OF PATIENTS HOSPITALIZED WITH ACUTE CORONARY SYNDROMES Chevalier P, Lamotte M Research Poster PCV169 THE ECONOMIC BURDEN OF POOR ADHERENCE TO STATINS IN BELGIUM Ramos M, Caekelbergh K, Lamotte M Research Poster PMH2 RISK FACTORS FOR DEMENTIA DIAGNOSIS IN GERMAN PRIMARY CARE PRACTICES Wendschlag A, Jacob L, Kostev K, Bohlken J, Rapp MA Research Poster PMH3 COGNITIVE SYMPTOMS IN MAJOR DEPRESSIVE DISORDER AND THEIR ITALIAN PSYCHIATRISTS' PERCEPTION Pegoraro V, Cataldo N, Albert U, Brugnoli R, Caraci F, Dell'Osso BM, Di Sciascio G, Tortorella A, Vampini C Research Poster PMH7 TREATMENT CONTINUATION AND TREATMENT CHARACTERISTICS OF FOUR LONG ACTING ANTIPSYCHOTIC MEDICATIONS (PALIPERIDONE PALMITATE, RISPERIDONE MICROSPHERES, OLANZAPINE PAMOATE AND HALOPERIDOL DECANOATE) IN THE NETHERLANDS Denee TR, Geerts P, Sermon J, Decuypere F, Widrich C, Rijntjes R, Mulder CL Research Poster PMH45 DRUG UTILIZATION PATTERN OF LISDEXAMFETAMINE DIMESYLATE IN EUROPE Cook MN, Varughese S, Maxwell T, Thun B, Ehlken B, von Bredow D, Keja J Research Poster PMH48 THE ECONOMIC CONSEQUENCES OF THE USE OF ANTIDEPRESSANTS IN BELGIUM: PRESCRIBING BEHAVIOR AND MISUSE OF ANTIDEPRESSANTS Ramos M, Brouyère S, Caekelbergh K, Lamotte M Research Poster PMH49 THE ECONOMIC CONSEQUENCES OF THE USE OF ANTIDEPRESSANTS IN BELGIUM Caekelbergh K, Ramos M, Lamotte M Research Poster PSS26 INTRAVITRAEL AFLIBERCEPT INJECTION FOR THE TREATMENT OF VISUAL IMPAIRMENT DUE TO MACULAR OEDEMA SECONDARY TO BRANCH RETINAL VEIN OCCLUSION: COST-EFFECTIVENESS VERSUS RANIBIZUMAB Lovato E, Lloyd A, Wilson B, Wittrup-Jensen KU Research Poster 8 IMS Health Activities 9 November CODE TOPIC PRESENTERS TYPE IMS Health Real-World Evidence Solutions
- 9. 9 IMS Health Activities 9 & 10 November ISPOR 18th Annual European Congress, November 2015, Milan, Italy CODE TOPIC PRESENTERS TYPE 9NOV10NOV PCN10 PREVALENCE OF DEPRESSION AND ANXIETY AND THEIR RISK FACTORS IN WOMEN WITH BREAST CANCER IN GERMAN PRIMARY CARE Engelhard J, Bleicher L, Kostev K Research Poster PCN13 THERAPY OF DEPRESSION IN CANCER AND NON-CANCER PATIENTS IN GERMAN NEUROPSYCHIATRIC PRACTICES Ziegelbauer K, Engelhard J, Kostev K Research Poster PCN34 A DESCRIPTION OF REAL-WORLD TREATMENT WITH ABIRATERONE ACETATE IN METASTATIC CASTRATION-RESISTANT PROSTATE CANCER PATIENTS IN THE POST-CHEMOTHERAPY SETTING IN FRANCE AND THE NETHERLANDS Dearden L, Musingarimi P, Shalet N, Demuth D, Garcia Alvarez L, Muthutantri A, Venerus A, Lasry R, Hankins M, Maher T Research Poster PCN115 THE ANALYSIS OF INPATIENTS COST OF BREAST CANCER IN CHINA, 2011 Song S, Wang Z, Zhang M Research Poster PCN123 ESTIMATION OF DIRECT MEDICAL COSTS ASSOCIATED WITH TREATMENT OF METASTATIC MELANOMA IN SWITZERLAND Christoffersen P, Khan N, Lucas J, Christodoulopoulou A, Del Ponte A, Gutzwiller F Research Poster PCN233 CANCER IS ASSOCIATED WITH INTRAOPERATIVE AND POSTPROCEDURAL COMPLICATIONS AND DISORDERS Engelhard J, Jockwig A, Kostev K Research Poster PCN277 THE ITALIAN REGIONAL ACCESS OF NEW CANCER DRUGS: AN EXAMPLE IN FOUR REGIONS Visentin E, Heiman F, Ripellino C Research Poster PCN319 4+ YEARS OF AMNOG – CLINICAL DRIVERS FOR SUCCESSFUL DOSSIER SUBMISSIONS IN ONCOLOGY Dehnen J, Goldhagen K, Petry D Research Poster PCN353 CURRENT TREATMENT PATTERNS IN PATIENTS WITH METASTATIC MELANOMA: A RETROSPECTIVE CLAIMS DATABASE ANALYSIS IN THE UNITED STATES (US) Chen Y, Ma Q, Hines DM, Zhao Z, Munakata J, Barber BL Research Poster PHP47 A COMPARISON OF TIME TO LAUNCH AND REIMBURSEMENT FOR NEW MEDICINES ACROSS DEVELOPED COUNTRIES Hickson SS, Skinner B, Bosnic N, Smith A, Zhang Y, Millson B Research Poster PHP100 APPRAISING THE COST OF PHYSICIAN VISITS AND TECHNICAL PROCEDURES IN FRANCE IN THE AGE OF OPEN DATA Sherwood A, Maurel F, Colin X Research Poster PHP132 THE ECONOMIC CONSEQUENCES OF THE USE OF ANTIBIOTICS IN BELGIUM Caekelbergh K, Ramos M, Lamotte M Research Poster PHP136 AVOIDABLE HOSPITALIZATIONS DUE TO MEDICATION ERRORS IN BELGIUM Ramos M, Caekelbergh K, Lamotte M Research Poster PHP139 LISTE-EN-SUS REFORM IN FRANCE - WHAT ARE THE CONSEQUENCES? Mitrano M, Flostrand S Research Poster PHP176 ITALIAN LAW 326/2003 FOR THE REIMBURSEMENT OF ORPHAN AND LIFE SAVING DRUGS AWAITING MARKET ENTRY: APPROVALS, REJECTIONS AND METHODS IN AIFA'S EVALUATION PROCESS BETWEEN JANUARY 2013 AND MAY 2015 Prada M, Bertozzi C, Proietti B, Urbinati D Research Poster PHP215 FROM CENTRALIZED MARKETING AUTHORIZATION TO NATIONAL REIMBURSEMENT – A CHALLENGING JOURNEY FOR NEW MEDICAL PRODUCTS WITH PLACEBO CONTROLLED TRIALS Eheberg D, Paulus G, Dannemann S, Batscheider A Research Poster PHP220 MANAGED ENTRY AGREEMENTS IN THE ITALIAN MARKET BETWEEN JUNE 2005 AND JUNE 2015 Tettamanti A, Urbinati D, Noble M Research Poster PHP260 DOES CONDITIONAL MARKETING AUTHORISATION INFLUENCE MARKET ACCESS IN FRANCE, ENGLAND, AND GERMANY? Kaaniche A, Troubat A, Sherwood A Research Poster PHP324 REFORMING DRUG PRICING AND PATIENT ACCESS SYSTEMS TO SUPPORT UNIVERSAL COVERAGE IN DEVELOPING COUNTRIES Shankar R, Hickson SS Research Poster
- 10. IMS Health Real-World Evidence Solutions 10 IMS Health Activities 10 & 11 November CODE TOPIC PRESENTERS TYPE 10NOV11NOV PIN9 PUBLIC HEALTH OUTCOMES OF PAEDIATRIC INFLUENZA VACCINATION WITH AN INTRANASAL TETRAVALENT LIVE ATTENUATED VACCINE IN BELGIUM USING A DYNAMIC TRANSMISSION MODEL Gerlier L, Lamotte M, Dos Santos Mendes S, Schwehm M, Eichner M Research Poster PDB13 A CROSS-SECTIONAL STUDY ON INSULIN TREATMENTS AND GLYCEMIC CONTROL IN TYPE 2 DIABETES IN FRANCE, ITALY, GERMANY, UK AND SPAIN Phan T, Boutmy E, Coulombel N Research Poster PDB16 CARDIOVASCULAR OUTCOMES OF ANTIDIABETIC THERAPY - RESULTS OF A LITERATURE SEARCH Greiner R, Eheberg D, Paulus G, Batscheider A Research Poster PDB40 HOSPITALIZATION COST AND LENGTH OF STAY ASSOCIATED WITH OPHTHALMOLOGICAL SURGERY DEPENDING ON THE DIABETIC STATUS Chevalier P, Lamotte M Research Poster PDB56 COST-EFFECTIVENESS OF DULAGLUTIDE 1.5MG ONCE WEEKLY FOR THE TREATMENT OF PATIENTS WITH TYPE TWO DIABETES MELLITUS IN SWEDEN Raibouaa A, Borgeke H, Alexiou D, Lowin J, Norrbacka K Research Poster PMS3 INCREASED RISK OF OSTEOPOROSIS IN DEPRESSED PATIENTS: A REAL-WORLD DATA STUDY CONDUCTED IN ITALY Heiman F, Moretti R, Pegoraro V, Cataldo N Research Poster PMS7 REDUCTION IN C-REACTIVE PROTEIN WITH BIOLOGIC DRUGS IN RHEUMATOID ARTHRITIS AND SPONDYLITIS PATIENTS IN GERMAN RHEUMATOLOGIST PRACTICES Gossen N, Kostev K Research Poster PMS68 BIOLOGICAL AGENTS FOR PATIENTS WITH RHEUMATOID ARTHRITIS WHO HAD FAILED TREATMENT WITH METHOTREXATE IN THE SPANISH CLINICAL SETTING: A COST-EFFECTIVENESS ANALYSIS Sánchez R, Restovic G, Planellas L Research Poster PMS90 DISPENSING FREQUENCY AMONG PATIENTS WITH RHEUMATOID ARTHRITIS TREATED WITH RITUXIMAB IN ENGLAND Tsoumani E, McCann E, Tham R, Yu E Research Poster PSY5 HOW ARE PAIN TREATMENT RESPONSE RATES IN PRIMARY CARE INFLUENCED BY CO-PRESCRIPTION OF CYP2D6 INHIBITORS? Pockett RD, O'Leary CJ, Anderson P, Nasser A, Winfield TG, Ansell D Research Poster PSY45 THE BUDGET IMPACT OF ORPHAN DRUGS IN THE US AND CANADA: A 2007-2013 MIDAS SALES DATA ANALYSIS Divino V, DeKoven M, Kim T, Kleinrock M, Wade RL, Kaura S Research Poster PSY51 ASSESSING THE BURDEN OF SYSTEMIC LUPUS ERYTHEMATOSUS IN BELGIUM USING A LONGITUDINAL HOSPITAL DATABASE Gerlier L, Lamotte M, Chevalier P Research Poster PSY98 HEALTH-RELATED QUALITY OF LIFE (HRQOL) IN SPLENECTOMIZED IMMUNE THROMBOCYTOPENIA (ITP) PATIENTS – A TARGETED LITERATURE REVIEW Lebioda A, Batscheider A Research Poster PSY124 THE ITALIAN 648/96 LIST: APPROVALS, REJECTIONS AND METHODS IN AIFA'S EVALUATION PROCESS BETWEEN JANUARY 2013 AND MAY 2015 Prada M, Bertozzi C, Proietti B, Urbinati D Research Poster IP8 THE COST OF NO EUROPE: ARE THERE COSTS AND CONSEQUENCES OF LOCALIZED OR CENTRALIZED ASSESSMENT OF RELATIVE EFFICACY? Kent A, Rappagliosi A, Longson C, Keja J Issue Panel W8 EVIDENCE SYNTHESIS BASED ON AGGREGATE AND INDIVIDUAL-LEVEL DATA: CONSIDERATIONS FOR USE IN HTA DECISION MAKING Reason T, Saramago Goncalves P, Asukai Y, Abrams KR Workshop ENRICHED REAL-WORLD DATA (RWD) STUDIES: TAPPING INTO THE GROWING USE OF PATIENT-LEVEL DATA TO OPTIMIZE OBSERVATIONAL STUDY DESIGN AND EXECUTION Bourke A, Hiller J, Engel P, Shaw A, Brannman L Educational Symposium W31 NETWORK META ANALYSIS MODELS FOR DOSE-RESPONSE AND CLASS EFFECTS IN DECISION MAKING Owen RK, Thorlund K, Mawdsley D, Reason T Workshop PRM69 PATIENT HETEROGENEITY IN COST-EFFECTIVENESS MODELS FOR CHRONIC OBSTRUCTIVE PULMONARY DISEASE (COPD): ARE CURRENT MODELS SUITABLE TO EVALUATE PERSONALIZED MEDICINE HoogendoornM,FeenstraT,AsukaiY, BriggsA,BorgS,dalNegroR,HansenRN, JanssonS,WackerM,RisebroughN, SamyshkinY,LeidlR,Ruttenvan-MölkenM Research Poster PRM72 CONTRASTING PREDICTIONS OF CARDIOVASCULAR INCIDENCE DERIVED FROM ALTERNATIVE RISK PREDICTION MODELS IN TYPE 1 DIABETES McEwan P, Foos V, Lamotte M Research Poster
- 11. ISPOR 18th Annual European Congress, November 2015, Milan, Italy 1111 IMS Health Activities 11 November CODE TOPIC PRESENTERS TYPE 11NOV PRM74 CONTRASTING MODEL PREDICTED LIFE EXPECTANCY IN PATIENTS WITH TYPE 2 DIABETES ACROSS DIFFERENT MORTALITY RISK PREDICTION MODELS VERSUS DATA FROM THE CANADIAN CHRONIC DISEASE SURVEILLANCE SYSTEM McEwan P, Foos V, Lamotte M Research Poster PRM84 THE IMPORTANCE OF ACCOUNTING FOR BASELINE HYPOGLYCAEMIA FREQUENCY WHEN MODELLING HYPOGLYCAEMIA DISUTILITY IN TYPE 1 DIABETES MELLITUS McEwan P, Lamotte M, Foos V Research Poster PRM85 VALIDATING APPROACHES TO MODELLING END-STAGE RENAL DISEASE USING THE IMS CORE DIABETES MODEL McEwan P, Foos V, Lamotte M Research Poster PRM88 THE IMPACT OF BASELINE HBA1C AND HBA1C TRAJECTORIES ON TIME TO THERAPY ESCALATION IN TYPE 2 DIABETES MELLITUS McEwan P, Foos V, Lamotte M Research Poster PRM98 INVESTIGATING THE IMPACT OF CONTEMPORARY RISK FACTORS FOR DIABETES COMPLICATIONS AND THEIR EVOLUTION ON RISK PREDICTION USING THE UKPDS 82 EQUATIONS McEwan P, Foos V, Lamotte M Research Poster PRM111 THE ROLE OF PATIENT-LEVEL DATA IN ASSESSING HEALTH ECONOMIC VALUE: A CASE STUDY USING EDGE AND THE CORE DIABETES MODEL Foos V, McEwan P, Evans M, Paldanius P Research Poster PRM130 USING MACHINE LEARNING TO DETECT PATIENTS WITH UNDIAGNOSED RARE DISEASES: AN APPLICATION OF SUPPORT VECTOR MACHINES TO A RARE ONCOLOGY DISEASE Rigg J, Lodhi H, Nasuti P Research Poster PRM228 SYSTEMATIC LITERATURE REVIEW OF ADJUNCTIVE ANTI-EPILEPTIC DRUG TRIALS IN PATIENTS WITH PRIMARY GENERALIZED TONIC-CLONIC SEIZURES ILLUSTRATES CHANGES IN STANDARD OF CARE OVER 12-20 YEARS Tsong WH, Gomez-Ulloa D, Li H, Forsythe A, Kramer L Research Poster PRM246 NORDIC LONGITUDINAL DATA FROM ELECTRONIC MEDICAL RECORDS AND FULL POPULATION NATIONAL REGISTERS: UNIQUE OPPORTUNITIES FOR NEW INSIGHTS IN BENEFIT OF DIABETES PATIENTS Lindh A, Persson F, Sobocki P, Bodegard J, Lindarck N Research Poster PRM250 FILLING THE GAP BETWEEN RISK/BENEFIT ASSESSMENT FOR DRUGS AND RISK ASSESSMENT FOR CONSUMER GOODS Hofmann-Xu L, Bonduelle D, Plantör S Research Poster PRM264 VALIDATION OF SOCIAL MEDIA ANALYSIS FOR OUTCOMES RESEARCH: IDENTIFICATION OF DRIVERS OF SWITCHES BETWEEN ORAL AND INJECTABLE THERAPIES FOR MULTIPLE SCLEROSIS Risson V, Saini D, Bonzani I, Huisman A, Olson M Research Poster PIH18 A COST-EFFECTIVENESS EVALUATION COMPARING BIOSIMILAR BEMFOLA TO GONAL-F FOR THE TREATMENT OF INFERTILITY IN AN ITALIAN CONTEXT Ripellino C, Visentin E, Gizzo S, Bühler K Research Poster PND41 COST-EFFECTIVENESS ANALYSIS OF DELAYED-RELEASE DIMETHYL FUMARATE FOR THE TREATMENT OF RELAPSING REMITTING MULTIPLE SCLEROSIS IN SPAIN Gasche D, Restovic G, Casado V, Ramírez-Boix P, Martínez Lopez J Research Poster PND66 COMPARISON OF COMPLIANCE AND DISCONTINUATION RATES AMONG MS PATIENTS TREATED WITH FINGOLIMOD AND OTHER DISEASE-MODIFYING THERAPIES: A CANADIAN RETROSPECTIVE CLAIMS ANALYSIS Haddad P, Duquette P, Yeung M, Lamarche A, Fraelic A, Chan S Research Poster Seeking a new challenge? We are currently looking for exceptional, talented individuals at all levels globally to join our international Real-World Evidence Solutions team. Please ask at the IMS Health stand during ISPOR or email our global talent acquisition manager at RWESrecruiting@imshealth.com for further information.
- 12. ©2015 IMS Health Incorporated and its affiliates. All rights reserved. Trademarks are registered in the United States and in various other countries. ORB01324 IMS Health Real-World Evidence Solutions is based in 20 countries worldwide with regional headquarters in RWEinfo@imshealth.com www.imshealth.com/rwe Europe 210 Pentonville Road London N1 9JY United Kingdom Tel: +44 (0) 20 3075 4800 The Americas One IMS Drive Plymouth Meeting Pennsylvania 19462 USA Tel: +1 (484) 567 6461 Latin America Insurgentes Sur # 2375 5th Floor Col. Tizapan México D.F.- C.P. 01090 México Tel: +52 55 5089 5205 Asia Pacific & Japan 8 Cross Street #21-01/02/03 Singapore 048424 Singapore Tel: +65 6412 7365 Toranomon Towers Office 4-1-28 Toranomon Minato-ku Tokyo 150-0001 Japan Tel: +81 3 5425 9541 IMS Health Real-World Evidence Solutions Bibliography Our research expertise and therapy area knowledge are captured in more than 3,500 publications, spanning virtually all therapy areas and projects completed in over 50 countries worldwide. Pick up a copy of the latest IMS Health Real-World Evidence Solutions Bibliography of published papers and presentations (2013-2015) incorporating publications from Cegedim Strategic Data, now part of IMS Health, from our stand at ISPOR or visit www.imsrwebibliography.com to explore our database online.